You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
|
|---|---|
| Published in |
Journal of Thoracic Oncology, September 2016
|
| DOI | 10.1016/j.jtho.2016.09.131 |
| Pubmed ID | |
| Authors |
Sai-Hong Ignatius Ou, Ramaswamy Govindan, Keith D. Eaton, Gregory A. Otterson, Martin E. Gutierrez, Alain C. Mita, Athanassios Argiris, Nicoletta M. Brega, Tiziana Usari, Weiwei Tan, Steffan N. Ho, Francisco Robert |
| Abstract |
This phase I trial was conducted to determine the safety, maximum tolerated dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients with advanced non-squamous non-small cell lung cancer (NSCLC). NSCLC patients with an Eastern Cooperative Oncology Group performance status of 0-2 after failure of 1-2 prior chemotherapy regimens were eligible. Erlotinib 100 mg was given continuously once daily (QD) starting between day -14 and -7; crizotinib 200 mg twice daily (BID; dose level 1) or 150 mg BID (dose level -1) was added continuously beginning on treatment cycle 1, day 1. Potential pharmacokinetic interactions between crizotinib and erlotinib were evaluated. Twenty-seven patients received treatment; 26 received crizotinib plus erlotinib. Common adverse events were diarrhea, rash, decreased appetite, and fatigue. Dose-limiting toxicities were dehydration, diarrhea, dry eye, dysphagia, dyspepsia, esophagitis and vomiting. The MTD was crizotinib 150 mg BID with erlotinib 100 mg QD. Crizotinib increased erlotinib area under the concentration-time curve 1.5-fold (dose level -1) and 1.8-fold (dose level 1). The crizotinib plasma level appeared to be unaffected by erlotinib coadministration. Two patients whose tumors harbored activating epidermal growth factor receptor mutations achieved confirmed partial responses, one at each crizotinib dose level. The MTD of the crizotinib-erlotinib combination in patients with advanced NSCLC was crizotinib 150 mg BID with erlotinib 100 mg QD, below the approved dose of either agent. The phase II portion of the study was not initiated. |
Mendeley readers
The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 69 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 14% |
| Student > Master | 9 | 13% |
| Other | 7 | 10% |
| Student > Ph. D. Student | 6 | 9% |
| Student > Bachelor | 4 | 6% |
| Other | 13 | 19% |
| Unknown | 20 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 30% |
| Nursing and Health Professions | 6 | 9% |
| Chemistry | 5 | 7% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Business, Management and Accounting | 1 | 1% |
| Other | 6 | 9% |
| Unknown | 25 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 October 2016.
All research outputs
#22,759,452
of 25,374,647 outputs
Outputs from Journal of Thoracic Oncology
#3,268
of 3,511 outputs
Outputs of similar age
#290,537
of 330,687 outputs
Outputs of similar age from Journal of Thoracic Oncology
#50
of 56 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,511 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,687 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 56 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.